Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition

John S K Kauwe, Carlos Cruchaga, Kevin Mayo, Chiara Fenoglio, Sarah Bertelsen, Petra Nowotny, Daniela Galimberti, Elio Scarpini, John C. Morris, Anne M. Fagan, David M. Holtzman, Alison M. Goate

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

There is substantial evidence that cerebrospinal fluid (CSF) levels of both Aβ42 and tau/ptau are promising biomarkers for Alzheimer's disease (AD). We show that both Aβ and tau exhibit more than 10-fold interindividual variation in CSF levels suggesting that these biomarkers may also be effectively used as endophenotypes for genetic studies of AD. To test the role of common variation in the gene encoding microtubule associated protein tau (MAPT) in influencing CSF tau/ptau levels, we genotyped 21 MAPT single nucleotide polymorphisms (SNPs) in 313 individuals and tested for association with CSF tau/ptau levels. We identified alleles of several SNPs that show association with increased CSF tau/ptau levels. When CSF Aβ42 levels were used to stratify the sample into those with and without likely Aβ deposition in the brain the association was only observed in individuals with evidence of Aβ deposition. This association was replicated in an independent CSF series. When these SNPs were evaluated in a late-onset AD case control series the alleles associated with higher CSF tau/ptau were associated with an earlier age at onset but had no effect on risk for AD. In vivo gene expression studies show that these alleles are associated with increased MAPT mRNA levels in individuals with evidence of brain Aβ deposition. This endophenotype-based approach provides evidence for a gene (MAPT SNPs)-physiological environment (Aβ deposition) interaction that places changes in CSF tau after Aβ deposition and suggest that this interaction predisposes for the development of tauopathy and accelerated disease progression.

Original languageEnglish
Pages (from-to)8050-8054
Number of pages5
JournalProceedings of the National Academy of Sciences of the United States of America
Volume105
Issue number23
DOIs
Publication statusPublished - Jun 10 2008

Fingerprint

Microtubule-Associated Proteins
Amyloid
Cerebrospinal Fluid
Single Nucleotide Polymorphism
Alzheimer Disease
Endophenotypes
Alleles
Biomarkers
Tauopathies
Brain
Age of Onset
Genes
Disease Progression
Gene Expression
Messenger RNA

Keywords

  • Alzheimer's disease
  • Genetics

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. / Kauwe, John S K; Cruchaga, Carlos; Mayo, Kevin; Fenoglio, Chiara; Bertelsen, Sarah; Nowotny, Petra; Galimberti, Daniela; Scarpini, Elio; Morris, John C.; Fagan, Anne M.; Holtzman, David M.; Goate, Alison M.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 105, No. 23, 10.06.2008, p. 8050-8054.

Research output: Contribution to journalArticle

Kauwe, John S K ; Cruchaga, Carlos ; Mayo, Kevin ; Fenoglio, Chiara ; Bertelsen, Sarah ; Nowotny, Petra ; Galimberti, Daniela ; Scarpini, Elio ; Morris, John C. ; Fagan, Anne M. ; Holtzman, David M. ; Goate, Alison M. / Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. In: Proceedings of the National Academy of Sciences of the United States of America. 2008 ; Vol. 105, No. 23. pp. 8050-8054.
@article{53f707bbf76c4861a1d425c8d02648e8,
title = "Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition",
abstract = "There is substantial evidence that cerebrospinal fluid (CSF) levels of both Aβ42 and tau/ptau are promising biomarkers for Alzheimer's disease (AD). We show that both Aβ and tau exhibit more than 10-fold interindividual variation in CSF levels suggesting that these biomarkers may also be effectively used as endophenotypes for genetic studies of AD. To test the role of common variation in the gene encoding microtubule associated protein tau (MAPT) in influencing CSF tau/ptau levels, we genotyped 21 MAPT single nucleotide polymorphisms (SNPs) in 313 individuals and tested for association with CSF tau/ptau levels. We identified alleles of several SNPs that show association with increased CSF tau/ptau levels. When CSF Aβ42 levels were used to stratify the sample into those with and without likely Aβ deposition in the brain the association was only observed in individuals with evidence of Aβ deposition. This association was replicated in an independent CSF series. When these SNPs were evaluated in a late-onset AD case control series the alleles associated with higher CSF tau/ptau were associated with an earlier age at onset but had no effect on risk for AD. In vivo gene expression studies show that these alleles are associated with increased MAPT mRNA levels in individuals with evidence of brain Aβ deposition. This endophenotype-based approach provides evidence for a gene (MAPT SNPs)-physiological environment (Aβ deposition) interaction that places changes in CSF tau after Aβ deposition and suggest that this interaction predisposes for the development of tauopathy and accelerated disease progression.",
keywords = "Alzheimer's disease, Genetics",
author = "Kauwe, {John S K} and Carlos Cruchaga and Kevin Mayo and Chiara Fenoglio and Sarah Bertelsen and Petra Nowotny and Daniela Galimberti and Elio Scarpini and Morris, {John C.} and Fagan, {Anne M.} and Holtzman, {David M.} and Goate, {Alison M.}",
year = "2008",
month = "6",
day = "10",
doi = "10.1073/pnas.0801227105",
language = "English",
volume = "105",
pages = "8050--8054",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "23",

}

TY - JOUR

T1 - Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition

AU - Kauwe, John S K

AU - Cruchaga, Carlos

AU - Mayo, Kevin

AU - Fenoglio, Chiara

AU - Bertelsen, Sarah

AU - Nowotny, Petra

AU - Galimberti, Daniela

AU - Scarpini, Elio

AU - Morris, John C.

AU - Fagan, Anne M.

AU - Holtzman, David M.

AU - Goate, Alison M.

PY - 2008/6/10

Y1 - 2008/6/10

N2 - There is substantial evidence that cerebrospinal fluid (CSF) levels of both Aβ42 and tau/ptau are promising biomarkers for Alzheimer's disease (AD). We show that both Aβ and tau exhibit more than 10-fold interindividual variation in CSF levels suggesting that these biomarkers may also be effectively used as endophenotypes for genetic studies of AD. To test the role of common variation in the gene encoding microtubule associated protein tau (MAPT) in influencing CSF tau/ptau levels, we genotyped 21 MAPT single nucleotide polymorphisms (SNPs) in 313 individuals and tested for association with CSF tau/ptau levels. We identified alleles of several SNPs that show association with increased CSF tau/ptau levels. When CSF Aβ42 levels were used to stratify the sample into those with and without likely Aβ deposition in the brain the association was only observed in individuals with evidence of Aβ deposition. This association was replicated in an independent CSF series. When these SNPs were evaluated in a late-onset AD case control series the alleles associated with higher CSF tau/ptau were associated with an earlier age at onset but had no effect on risk for AD. In vivo gene expression studies show that these alleles are associated with increased MAPT mRNA levels in individuals with evidence of brain Aβ deposition. This endophenotype-based approach provides evidence for a gene (MAPT SNPs)-physiological environment (Aβ deposition) interaction that places changes in CSF tau after Aβ deposition and suggest that this interaction predisposes for the development of tauopathy and accelerated disease progression.

AB - There is substantial evidence that cerebrospinal fluid (CSF) levels of both Aβ42 and tau/ptau are promising biomarkers for Alzheimer's disease (AD). We show that both Aβ and tau exhibit more than 10-fold interindividual variation in CSF levels suggesting that these biomarkers may also be effectively used as endophenotypes for genetic studies of AD. To test the role of common variation in the gene encoding microtubule associated protein tau (MAPT) in influencing CSF tau/ptau levels, we genotyped 21 MAPT single nucleotide polymorphisms (SNPs) in 313 individuals and tested for association with CSF tau/ptau levels. We identified alleles of several SNPs that show association with increased CSF tau/ptau levels. When CSF Aβ42 levels were used to stratify the sample into those with and without likely Aβ deposition in the brain the association was only observed in individuals with evidence of Aβ deposition. This association was replicated in an independent CSF series. When these SNPs were evaluated in a late-onset AD case control series the alleles associated with higher CSF tau/ptau were associated with an earlier age at onset but had no effect on risk for AD. In vivo gene expression studies show that these alleles are associated with increased MAPT mRNA levels in individuals with evidence of brain Aβ deposition. This endophenotype-based approach provides evidence for a gene (MAPT SNPs)-physiological environment (Aβ deposition) interaction that places changes in CSF tau after Aβ deposition and suggest that this interaction predisposes for the development of tauopathy and accelerated disease progression.

KW - Alzheimer's disease

KW - Genetics

UR - http://www.scopus.com/inward/record.url?scp=45849122478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45849122478&partnerID=8YFLogxK

U2 - 10.1073/pnas.0801227105

DO - 10.1073/pnas.0801227105

M3 - Article

VL - 105

SP - 8050

EP - 8054

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 23

ER -